Jul 31, 2026
FDA Advisory Committee Votes 10-3 in Favor of Replimune's RP1 Efficacy Data from Ignyte Study
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.
1 source
00